bivamelagon vs setmelanotide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypothalamic Obesity

Shared mechanism: MC4R · full Hypothalamic Obesity pipeline

bivamelagon

Developed by Rhythm Pharmaceuticals under a licence from LG Chem

Phase 2 in Hypothalamic Obesitysmall molecule
Partial signal

NCT06046443 · Phase 2 · completed

This was a randomized, triple-blind, placebo-controlled Phase 2 trial in 28 participants with hypothalamic obesity. All three LB54640 doses produced a statistically significant reduction in BMI at 14 weeks compared with placebo, for example the highest dose: -9.3% vs +2.2% with placebo, p=0.0004, meeting the trial primary comparison, though the very small number of participants limits how confidently this result generalizes.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: April 2028 · NCT07156578 (registry estimate)

Reported efficacy

Mean percentage change in BMI (From Baseline to Week 14): Mean % change in BMI at Week 14: 600mg -9.3% (p=0.0004), 400mg -7.7% (p=0.0002), 200mg -2.7% (p=0.0180), placebo +2.2% (met)

Result source: NCT06046443

setmelanotide · Imcivree

Marketed by Rhythm Pharmaceuticals

Approved in Hypothalamic Obesitypeptide
Reliable signal

NCT05774756 · Phase 3 · active, not recruiting

This was a randomized, triple-blind, placebo-controlled trial whose primary endpoint, percent change in BMI, was clearly met (difference of about 20 percentage points, p<0.0001). The trial enrolled the 120 pivotal participants its reported power calculation required.

Next expected readout: March 2027 · NCT06760546 (registry estimate)

Reported efficacy

Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) (met)

Result source: NCT05774756

Results for Hypothalamic Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. bivamelagon: 0 of 4 rows · setmelanotide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbivamelagonsetmelanotide
Dropout rate—
11.1%a
NCT04725240 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
11.1%a
NCT04725240 · Phase 2 · registry result, not featured evidence
Serious AEs—
5.6%a
NCT04725240 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
a
nausea 61.1%
skin hyperpigmentation 33.3%
vomiting 33.3%
NCT04725240 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

bivamelagon

BMI -9.3% vs 2.2% placebo @ 14wk600mg
percent change · % of baseline
NCT06046443 · Phase 2 · sponsor-reported, not registry data
show 2 more results
-7.7% vs 2.2% placebo @ 14wk400mg
NCT06046443 · Phase 2 · sponsor-reported, not registry data
-2.7% vs 2.2% placebo @ 14wk200mg
NCT06046443 · Phase 2 · sponsor-reported, not registry data

setmelanotide

BMI 5% Reduction 88.9% (n=18) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT04725240 · Phase 2 · registry result, not featured evidence
BMI Z-Score 0 2 or Weight Loss 5% Composite 88.9% (n=18) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT04725240 · Phase 2 · registry result, not featured evidence
BMI Z-Score 0 2 Reduction 92.3% (n=13) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT04725240 · Phase 2 · registry result, not featured evidence
Weight Loss 5% 80% (n=5) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT04725240 · Phase 2 · registry result, not featured evidence
Waist Circumference Change -10.275 cm @ 16wk
absolute change · cm
No placebo or comparator arm
NCT04725240 · Phase 2 · registry result, not featured evidence
Hunger -1.49 score @ 16wk
absolute change · score
No placebo or comparator arm
NCT04725240 · Phase 2 · registry result, not featured evidence
Hunger -3.122 score @ 16wk
absolute change · score
No placebo or comparator arm
Average hunger
NCT04725240 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bivamelagon's landscape · setmelanotide's landscape